Peer-reviewed veterinary case report
Recombinant feline interferon omega helps cats with calicivirus mouth
By Hennet, Philippe R et al.·Published in Journal of feline medicine and surgery·2011·Clinique vé, France·View original on PubMed →
PetCaseFinder translated the abstract of this peer-reviewed paper into plain English so pet owners can read it. We do not publish original research — every detail traces back to the citation above. How we work →
Original publication title: Comparative efficacy of a recombinant feline interferon omega in refractory cases of calicivirus-positive cats with caudal stomatitis: a randomised, multi-centre, controlled, double-blind study in 39 cats.
- Species:
- cat
Plain-English summary
A group of 39 cats with severe mouth sores and pain from calicivirus were treated for chronic caudal stomatitis (a painful inflammation of the mouth). They received either a new treatment called recombinant feline interferon omega or a common steroid medication. Over 90 days, the cats given the interferon showed significant improvement in their mouth lesions and less pain compared to those on steroids. While both treatments had benefits, the interferon seemed to help more with pain relief at certain points during the study.
People also search for: cat mouth sores treatment · calicivirus in cats · feline interferon omega for stomatitis · cat pain relief options
Abstract
Chronic caudal stomatitis with alveolar/buccal mucositis in calicivirus-positive cats is the most severe presentation of feline chronic gingivostomatitis. Refractory cases are helped by antibiotic and anti-inflammatory treatments often including glucocorticoids. In order to evaluate the comparative efficacy of oromucosal administration of recombinant feline interferon omega (rFeIFN-ω) versus oral administration of glucocorticoids, a randomised, multi-centre, controlled, double-blind study was performed in 39 cats. The progression of behavioural, clinical and lesional scores was assessed over 90 days. Daily oromucosal treatment with 0.1 MU of rFeIFN-ω was associated with a significant improvement of clinical lesions (caudal stomatitis and alveolar/buccal mucositis) and a decrease of pain scores from D0 to D90. Although no such statistical improvement was noticed in the prednisolone group, there was, however, no significant difference between the two groups for most of the parameters, except pain at D60 and D90.
Find similar cases for your pet
PetCaseFinder finds other peer-reviewed reports of pets with the same symptoms, plus a plain-English summary of what was tried across them.
Search related cases →Original publication on PubMed: https://pubmed.ncbi.nlm.nih.gov/21802033/